News

Bayer expands in Down Under
Enlarge image

BusinessGermany

Bayer expands in Down Under

09.08.2012 - Bayer CropScience expands its R&D in Australia by the establishment of a breeding centre for stress- and drought resistant GM wheat and rapeseed.

The Monheim-based arm of German agri-biotech giant Bayer AG plans to build a new breeding centre near Horsham (Western Victoria). Bayer’s €12m investment for the new centre aims at developing new wheat and rapeseed varieties with higher yields and productivity tailored to Australian conditions. Australia ranks as the 3rd largest exporter for wheat and the 2nd largest for oilseeds.

"With the demand for wheat and oilseeds growing worldwide, we drive our efforts towards producing new high-yielding varieties that are better able to withstand pests, diseases and able to thrive under environmental stresses like drought," said Dr. Mathias Kremer, Head of the BioScience business unit at Bayer CropScience. The investment is part of Bayer’s plan to expand its wheat breeding stations in Asia and Latin America, which include huge consumer markets for wheat.

Construction of the new breeding centre will start in the coming months with first local breeding programs expected to yield results for Australian farmers within the decade, according to Bayer CropScience.

Agribiotechnology is a stragic growth field for the company. According to current market estimates of Companies & Markets the global agri-biotech market was valued at US$13.7bn and is estimated to hit US$14.4bn by the end of this year. Growing at an compound annual growth rate (CGAR) of 11.4% the agri-biotech market is to reach a value of US$24.8bn by 2017. Asia-Pacific represents the fastest growing agri-biotech market with a CGAR of 14% until 2015. Transgenic seeds, developed by Bayer CropScience as one of the key market players, make up the bulk of the market.

BusinessSwitzerlandUK

23.04.2014 In an effort to focus on key businesses, pharma giant Novartis is joining forces with long-time rival GlaxoSmithKline in a multi-billion Euro asset exchange and an OTC joint venture.

FinanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)344.00 GBP12.6%
  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK73.5%
  • WILEX (D)0.81 EUR42.1%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • IMMUNICUM AB (S)16.40 SEK-36.9%

TOP

  • SILENCE THERAPEUTICS (UK)257.25 GBP6174.4%
  • IXICO (UK)66.50 GBP737.5%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014